Chronic Medical Therapy for Pheochromocytoma
Authors: KARL ENGELMAN
Journal: Annals of Internal Medicine (1964)

Article1 August 1964Chronic Medical Therapy for PheochromocytomaA Report of Four CasesKARL ENGELMAN, M.D., ALBERT SJOERDSMA, M.D., PH.D.KARL ENGELMAN, M.D.Search for more papers by this author, ALBERT SJOERDSMA, M.D., PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-2-229 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince the first successful operation for pheochromocytoma in 1927 (1), the treatment of choice for this condition has been surgical excision of the tumor. Pharmacological therapy with phentolamine methanesulfonate (Regitine®, Ciba Pharmaceutical Products) or phenoxybenzamine (Dibenzyline®, Smith, Kline & French) to prepare the patient with a pheochromocytoma for surgery and the use of phentolamine to control the paroxysmal hypertensive crises encountered during surgery have gained wide acceptance. However, the use of these adrenolytic drugs in the chronic treatment of patients with resectable pheochromocytoma or with medical contra-indications to surgery has not been widely reported. The results of chronic therapy with...References1. MAYO CH: Removal of a retroperitoneal tumor from a patient with paroxysmal hypertension. JAMA 89: 1049, 1929. Google Scholar2. CROUT JR: Determination of catecholamines in urine, in Standard Methods of the American Association of Clinical Chemists. Vol. 3, edited by SELIGSON, D., Academic Press, New York, 1960, p. 62. Google Scholar3. PISANO JJ: A simple analysis for normetaphrine and metanephrine in urine. Clin. Chim. Acta 5: 406, 1960. CrossrefMedlineGoogle Scholar4. PISANOCROUTABRAHAM JJJRD: Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin. Chim. Acta 7: 285, 1962. CrossrefMedlineGoogle Scholar5. OATES JA: Measurement of urinary tryptamine, tyramine, and serotonin, in Methods in Medical Research, Vol. 9, edited by QUASTEL, J. H., Year Book Medical Publishers, Chicago, 1960, p. 169. Google Scholar6. BRODIEKUNTZMANHIRSCHCOSTA BBRCNE: Effects of decarboxylase inhibition on the biosynthesis of brain monoamines. Life Sci. 3: 81, 1962. CrossrefGoogle Scholar7. KUNTZMANCOSTACREVELINGHIRSCHBRODIE RECCNBB: Inhibition of norepinephrine synthesis in mouse brain by blockage of dopamine-β-oxidase. Life Sci. 3: 85, 1962. CrossrefGoogle Scholar8. HANSSONFLEMINGCLARK ERMWG: Effect of some benzylhydrazines and benzyloxyamines on DOPA and 5-hydroxytryptophane decarboxylase in vivo. Int. J. Neurolpharm. 3: 177, 1964. Google Scholar9. BURKARDGEYPLETSCHER WPKFA: A new inhibitor of decarboxylase of aromatic amino acids. Experimentia 18: 411, 1962. CrossrefMedlineGoogle Scholar10. TISHERMANGREGGDANOWSKI SEFJTS: Familial pheochromocytoma. JAMA 182: 152, 1962. CrossrefMedlineGoogle Scholar11. ENGELMANSJOERDSMA KA: A new test for pheochromocytoma based on pressor responsiveness to tyramine. JAMA (In Press). Google Scholar12. ENGELMANWATTSKLINENBERGSJOERDSMASEEGMILLER KRWJAJE: Clinical, biochemical and physiological studies in a case of xanthinuria and pheochromocytoma. Amer. J. Med. (In Press). Google Scholar13. SZAKÁCSCANNON JEA: 1-Norepinephrine myocarditis. Amer. J. Clin. Path. 30: 425, 1958. CrossrefMedlineGoogle Scholar14. KLINE IK: Myocardial alterations associated with pheochromocytomas. Amer. J. Path. 38: 539, 1961. MedlineGoogle Scholar15. ALLENBANNONUPSONHUIZENGABASTRONWAUGH EVWGMKAJAJM: A new sympatholytic and adrenolytic drug: Clinical studies on pheochromocytoma and essential hypertension. Trans. Ass. Amer. Physicians 64: 109, 1951. MedlineGoogle Scholar16. ENGELMANMUELLERSJOERDSMA KPSA: Elevated plasma free fatty acids in patients with pheochromocytoma: Changes with therapy and correlations with the basal metabolic rate. New Eng. J. Med. 270: 865, 1964. CrossrefMedlineGoogle Scholar17. BELLAS JE: Nonsurgical pheochromocytoma. JAMA 185: 601, 1963. CrossrefMedlineGoogle Scholar18. ROYBHATIAMATHUR SBMLVS: Guanethidine and pheochromocytoma. Brit. Med. J. 1: 729, 1963. CrossrefMedlineGoogle Scholar19. GENEST J: Studies of guanethidine administration in 28 patients with arterial hypertension, in CIBA Symposium on Guanethidine. (Held at University of Tennessee College of Medicine, Memphis, Tennessee, April 22, 1960.) Ciba Pharmaceutical Products, Inc., Summit, New Jersey, 1960, p. 47. Google Scholar20. MCCUBBIN JW: The clinical and experimental pharmacology of guanethidine. Med. Clin. N. Amer. 45: 409, 1961. CrossrefGoogle Scholar21. PAGEHURLEYDUSTAN IHREHP: The prolonged treatment of hypertension with guanethidine. JAMA 175: 543, 1961. CrossrefMedlineGoogle Scholar22. OATESGILLESPIEUDENFRIENDSJOERDSMA JALSA: Decarboxylase inhibition and blood pressure reduction by α-methyl-3, 4-dihydroxy-DL-phenylalanine. Science 131: 1890, 1960. CrossrefMedlineGoogle Scholar23. GELFMANLANDAUMULROWFRIEDEWALDDALESSIO NASJPJWTDJ: Unresectable pheochromocytoma: Response to α-methyl-dihydroxy-L-phenylalanine. J. Chron. Dis. 16: 217, 1963. CrossrefMedlineGoogle Scholar24. GILLESPIEOATESCROUTSJOERDSMA LJAJRA: Clinical and chemical studies with α-methyl-dopa in patients with hypertension. Circulation 25: 281, 1962. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: KARL ENGELMAN, M.D.; ALBERT SJOERDSMA, M.D., PH.D.Affiliations: Bethesda, MarylandFrom the Experimental Therapeutics Branch, National Heart Institute, Bethesda, Maryland.Requests for reprints should be addressed to Albert Sjoerdsma, M.D., National Heart Institute, Bethesda, Maryland. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRecurrent phaeochromocytomaRisk of operation in a patient with unsuspected phaeochromocytomaRadiation Therapy of Metastatic Pheochromocytoma: Case Report and Review of the LiteraturePediatric malignant pheochromocytomaMalignant Pheochromocytoma Masquerading as Acute Pancreatitis—A Rare but Potentially Lethal OccurrenceBeta receptor antagonists in the treatment of heart failureLate presentation of bone metastases in phaeochromocytomaMeasurement and cardiovascular relevance of partial agonist activity (PAA) involving β1- and β2-adrenoceptorsEFFECT OF FUSARIC ACID (A DOPAMINE β-HYDROXYLASE INHIBITOR) ON PHAEOCHROMOCYTOMAHypertonieEffect of Phenoxybenzamine on Myocardial Cell Necroses and Blood Levels of Catecholamines in Pigs Subjected to StressPhaeochromocytoma and cardiomyopathyMalignant phaeochromocytoma in children: A case with neurofibromatosis and review of the literatureCardiomyopathy and phaeochromocytomaThe role of the adrenal gland in hypertensionThe management of the patient with catecholamine excessCatecholamine Measurements in Phaeochromocytoma: A ReviewPheochromocytoma10 PhaeochromocytomaDynamic left ventricular outflow tract obstruction associated with pheochromocytomaSevere hypertension in a child with ganglioneuroblastomaPhäochromozytomCatecholamines and the HeartEffects of work and acute beta-receptor blockade on myocardial noradrenaline release in congestive cardiomyopathyMalignant pheochromocytoma in childhood: Report of a case with familial neurofibromatosisDas NebennierenmarkPhaeochromocytomaPheochromocytoma: Recent experience with detection and managementSodium nitroprusside and lidocaine in the anaesthetic management of pheochromocytomaCardiomyopathy associated with amphetamine administrationSurgery of the AdrenalsPhaeochromocytomaObservations on Myocardial Function During Chronic Catecholamine OversecretionPheochromocytomaTachycardia-Aggravated Heart DiseaseTOBY R. ENGEL, M.D., CHARLES A. BUSH, M.D., STEPHEN F. SCHAAL, M.D.The Adrenal MedullaTherapeutic Alternatives in HypertensionPropranololHOWARD F. MORRELLI, M.D., F.A.C.P.Prolonged survival in malignant pheochromocytoma of the organ of zuckerkandl with pharmacological treatmentChemotherapeutic management of the hormone-secreting endocrine malignanciesPhaeochromocytoma with Catecholamine Cardiomyopathy Successfully Treated SurgicallyPheochromocytoma without hypertension presenting as cardiomyopathyPheochromocytoma masquerading as a cardiomyopathySystemic Hypertension in Children and AdolescentsManagement of patients with pheochromocytomaMalignant Pheochromocytoma with Pleural Metastasis of Unusually Long DurationHypertension in children and adolescents.II. Drug therapy5 The Biosynthesis and Metabolism of the CatecholaminesMalignant PheochromocytomaCatecholamine metabolism of manic-depressive illnessPheochromocytomaSurgery of the Adrenal GlandFurther Evaluation of the Tyramine Test for PheochromocytomaPhysiologic and Pharmacologic Considerations in the Management of PheochromocytomaDihydroxyphenylalanine secretion in a malignant pheochromocytomaPheochromocytoma: Current Concepts of Diagnosis and Treatment Combined Clinical Staff Conference at the National Institutes of HealthALBERT SJOERDSMA, M.D., PH.D., KARL ENGELMAN, M.D., THOMAS A. WALDMANN, M.D., LEE H. COOPERMAN, M.D., WILLIAM G. HAMMOND, M.D.Acute PheochromocytomaFocal Myocarditis Associated with PheochromocytomaSome biochemical aspects of treatment and diagnosis of hypertensionSome biochemical aspects of treatment and diagnosis of hypertensionINHIBITION OF CATECHOLAMINE SYNTHESIS IN MAN WITH ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASEClinical, physiological and biochemical studies of a patient with xanthinuria and pheochromocytoma 1 August 1964Volume 61, Issue 2Page: 229-241KeywordsCardiovascular therapyDrug therapyDrugsHeartHypertensionOral administrationPatientsPhenoxybenzaminePheochromocytomaSurgery ePublished: 1 December 2008 Issue Published: 1 August 1964 PDF downloadLoading ...